The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| BFRI | +15.99% | N/A | N/A | -99% |
| S&P | +13.19% | +87.83% | +13.42% | +46% |
Biofrontera, Inc. is a biopharmaceutical company, which engages in the commercialization of pharmaceutical products. It specializes in the treatment of dermatological conditions, caused primarily by exposure to sunlight that results in sun damage to the skin. The company is focused on the treatment of actinic keratosis and markets a topical antibiotic for treatment of impetigo. Its products include Ameluz and Xepi, its two prescription drugs, and BF-RhodoLED, a lamp used with Ameluz, for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company was founded on March 3, 2015 and is headquartered in Woburn, MA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $6.99M | -22.5% |
| Gross Profit | $4.92M | 22.3% |
| Gross Margin | 70.44% | 25.8% |
| Market Cap | $10.51M | 42.5% |
| Market Cap / Employee | $0.11M | 0.0% |
| Employees | 93 | 9.4% |
| Net Income | -$6.65M | -17.3% |
| EBITDA | -$6.07M | -30.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $3.42M | 18.9% |
| Accounts Receivable | $3.00M | -38.6% |
| Inventory | 4.3 | -33.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $4.60M | 1319.1% |
| Short Term Debt | $0.31M | -54.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -103.57% | -54.8% |
| Return On Invested Capital | -217.01% | -12.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$3.82M | -216.4% |
| Operating Free Cash Flow | -$3.82M | -216.5% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.29 | 1.60 | 13.46 | -2.14 | -444.51% |
| Price to Sales | 0.26 | 0.19 | 0.17 | 0.29 | 31.51% |
| Price to Tangible Book Value | 1.30 | 1.61 | 14.42 | -2.13 | -365.74% |
| Enterprise Value to EBITDA | -5.82 | -2.35 | -0.91 | -1.99 | 59.84% |
| Return on Equity | -390.9% | -385.0% | -531.5% | -1191.7% | 697.60% |
| Total Debt | $4.92M | $4.86M | $5.00M | $4.91M | 393.46% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
